Literature DB >> 24104886

Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation.

M Zaeem Cader1, Arthur Kaser.   

Abstract

The intestine and its immune system have evolved to meet the extraordinary task of maintaining tolerance to the largest, most complex and diverse microbial commensal habitat, while meticulously attacking and containing even minute numbers of occasionally incoming pathogens. While our understanding is still far from complete, recent studies have provided exciting novel insights into the complex interplay of the many distinct intestinal immune cell types as well as the discovery of entirely new cell subsets. These studies have also revealed how proper development and function of the intestinal immune system is dependent on its specific microbiota, which appears to have evolutionarily co-evolved. Here we review key immune cells that maintain intestinal homeostasis and, conversely, describe how altered function and imbalances may lead to inflammatory bowel disease (IBD). We highlight the latest developments within this field, covering the major players in IBD including intestinal epithelial cells, macrophages, dendritic cells, adaptive immune cells, and the newly discovered innate lymphoid cells, which appear of characteristic importance for immune function at mucosal surfaces. We set these mucosal immune pathways in the functional context of IBD risk genes where such insight is available. Moreover, we frame our discussion of fundamental biological pathways that have been elucidated in model systems in the context of results from clinical trials in IBD that targeted key mediators secreted by these cells, as an attempt of 'functional' appraisal of these pathways in human disease.

Entities:  

Keywords:  INFLAMMATORY BOWEL DISEASE; MUCOSAL IMMUNOLOGY

Mesh:

Year:  2013        PMID: 24104886     DOI: 10.1136/gutjnl-2012-303955

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  113 in total

Review 1.  Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?

Authors:  Tim Raine
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

2.  Differential regulation of proinflammatory cytokine expression by mitogen-activated protein kinases in macrophages in response to intestinal parasite infection.

Authors:  Mei Xing Lim; Chin Wen Png; Crispina Yan Bing Tay; Joshua Ding Wei Teo; Huipeng Jiao; Norbert Lehming; Kevin Shyong Wei Tan; Yongliang Zhang
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 3.  Unusual osseous metastases from rectal adenocarcinoma: a case report and review of the literature.

Authors:  T M Connelly; R P Piggott; R M Waldron; P O'Grady
Journal:  J Gastrointest Surg       Date:  2015-02-27       Impact factor: 3.452

Review 4.  Pathway-based approaches to the treatment of inflammatory bowel disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Transl Res       Date:  2015-09-07       Impact factor: 7.012

5.  Proliferation and apoptosis of Peyer's patches and its lymphocytes in experimental terminal ileitis.

Authors:  Wei Wang; Ailei Xu; Guohua Zhou; Mingfang Leng; Hongyu Zhou; Jun Yan
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

6.  Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.

Authors:  Heng Li; Chen Fan; Chunlan Feng; Yanwei Wu; Huimin Lu; Peilan He; Xiaoqian Yang; Fenghua Zhu; Qing Qi; Yuanzhuo Gao; Jianping Zuo; Wei Tang
Journal:  Br J Pharmacol       Date:  2019-05-17       Impact factor: 8.739

7.  Hypoxia inducible factor-1α-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease.

Authors:  M Sun; C He; W Wu; G Zhou; F Liu; Y Cong; Z Liu
Journal:  Clin Exp Immunol       Date:  2016-12-06       Impact factor: 4.330

Review 8.  Innate immunity in disease.

Authors:  David E Elliott; Sana S Siddique; Joel V Weinstock
Journal:  Clin Gastroenterol Hepatol       Date:  2014-03-12       Impact factor: 11.382

Review 9.  Border maneuvers: deployment of mucosal immune defenses against Toxoplasma gondii.

Authors:  S B Cohen; E Y Denkers
Journal:  Mucosal Immunol       Date:  2014-04-09       Impact factor: 7.313

10.  Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages.

Authors:  Shuji Mitsuhashi; Linda Feldbrügge; Eva Csizmadia; Masato Mitsuhashi; Simon C Robson; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.